Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic

Core Insights - Medtronic has successfully performed the first U.S. commercial surgical case using its FDA-cleared Hugo™ robotic-assisted surgery (RAS) system at Cleveland Clinic, marking a significant milestone in expanding access to minimally invasive surgery [1] Company Developments - The first procedure was a robotic-assisted prostatectomy conducted by Dr. Jihad Kaouk, who emphasized the technology's ability to customize surgical approaches for individual patients [1] - The Hugo RAS system received FDA clearance for urologic surgical procedures in December 2025, and its introduction is part of Medtronic's broader surgical offerings [1] Industry Trends - Urology has seen a high adoption rate of robotic technology, with approximately 80% of urologic abdominal surgeries in the U.S. currently performed with robotic assistance, indicating a strong trend towards robotic-assisted procedures across various specialties [1] - The Hugo RAS system's modular design aims to address operating room scheduling challenges and infrastructure limitations, potentially increasing patient access to the benefits of minimally invasive care [1] Clinical Research - Cleveland Clinic participated in the Expand URO Investigational Device Exemption (IDE) clinical study, which demonstrated that the Hugo RAS system met primary safety and effectiveness endpoints in urologic surgeries [1] - The system is expected to expand its indications into gynecologic and general surgery procedures, including hernia repair, further broadening its application in the surgical field [1]